CagriSema's Phase 3 readout is genuinely differentiated on weight loss magnitude, but the headline superiority claim carries a dose-selection caveat that will define every downstream regulatory and payer conversation. [1] In REIMAGINE 5, CagriSema 1.0 mg/1.0 mg achieved 12.4% weight loss versus tirzepatide 5 mg at 9.1% in adults with type 2 diabetes, with non-inferior HbA1c reduction — a Phase 3 RCT result, the highest evidence tier, against an active comparator. In REDEFINE 9, CagriSema delivered 21.0% weight reduction versus 2.0% for placebo in adults with overweight or obesity, also Phase 3 RCT. The 21.0% obesity figure is among the largest reported in a Phase 3 placebo-controlled obesity trial and positions CagriSema at the efficacy frontier of the GLP-1-anchored class. The critical structural problem is that tirzepatide 5 mg — the REIMAGINE 5 comparator — is the lowest approved maintenance dose. Multiple HTA bodies, including the PBAC, have confirmed that tirzepatide's clinical differentiation over semaglutide 1 mg was established at 10 mg and 15 mg, not 5 mg. [2][3] Network meta-analysis evidence places tirzepatide 15 mg at a mean difference of -17.97% and CagriSema at -17.84% in percent weight reduction — near-equivalent at maximum doses — which directly qualifies the REIMAGINE 5 superiority framing. [4] No precedent clears the full mechanistic-fit bar: CagriSema's amylin-plus-GLP-1 combination has no prior approved analogue, and tirzepatide (GIP-plus-GLP-1) is mechanistically distinct in its second pathway. HTA bodies across Korea, Italy, France, Canada, Australia, and the Netherlands have consistently penalized GLP-1-anchored agents for absent cardiovascular outcomes data and surrogate-only endpoint packages — a gap CagriSema has not closed. The sharpest risk is that payers will demand head-to-head data against tirzepatide 10 mg or 15 mg before granting premium formulary access, and that data does not yet exist.
REIMAGINE 5 and REDEFINE 9 are Phase 3 RCTs — the highest evidence tier — with statistically significant primary endpoints, but the tirzepatide 5 mg comparator in REIMAGINE 5 is the lowest approved maintenance dose, and network meta-analysis data suggest near-parity with tirzepatide 15 mg at maximum doses, limiting the superiority claim's scope.
| Indication | Type 2 diabetes |
| Drug | Cagrilintide and semaglutide |
| Mechanism of Action | amylin receptor agonist, GLP-1 receptor agonist |
| Company | Novo Nordisk |
| Trial Phase | Phase 3 |
| Trial Acronym | REIMAGINE 5, REDEFINE 9 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Endocrinology & Metabolic Diseases |
| Comparator Drug (REIMAGINE 5) | tirzepatide 5 mg |
| Comparator (REDEFINE 9) | placebo |
| Patient Population (REIMAGINE 5) | Adults with type 2 diabetes (inadequately controlled on metformin, SGLT2i, or both) |
| Patient Population (REDEFINE 9) | Adults with overweight or obesity (adjunct to diet & exercise) |
| CagriSema Dosage | 1.0 mg/1.0 mg |
| Primary Endpoints (REIMAGINE 5) | Change in HbA1c, Relative change in body weight |
| Primary Endpoints (REDEFINE 9) | Relative change in body weight, Proportion achieving ≥5% weight reduction |
| Regulatory Filing Type | New Drug Application |
| Regulatory Agency | U.S. Food and Drug Administration |
| Expected Regulatory Decision | Q4 2026 |
CagriSema Achieves Superior Weight Loss and HbA1c Reduction in Phase 3 Trials
Novo Nordisk announced positive topline results from two Phase 3 trials, REIMAGINE 5 and REDEFINE 9, for its investigational once-weekly CagriSema (cagrilintide and semaglutide). In REIMAGINE 5, CagriSema 1.0 mg/1.0 mg demonstrated superior weight loss of 12.4% compared to tirzepatide 5 mg (9.1%) and non-inferior HbA1c reduction in adults with type 2 diabetes. In REDEFINE 9, CagriSema 1.0 mg/1.0 mg achieved a significant weight reduction of 21.0% versus 2.0% for placebo in adults with overweight or obesity. The drug was well tolerated in both studies, with a safety profile consistent with previous findings.
- In the Phase 3 REIMAGINE 5 trial, CagriSema 1.0 mg/1.0 mg showed superior efficacy for weight loss, achieving an estimated average reduction of 12.4% from baseline, compared to 9.1% for tirzepatide 5 mg. Additionally, CagriSema confirmed non-inferiority in HbA1c reduction, with a 1.71% decrease versus 1.67% for tirzepatide, in adults with type 2 diabetes inadequately controlled on existing therapies.
- The Phase 3 REDEFINE 9 trial demonstrated that CagriSema 1.0 mg/1.0 mg provided a substantial weight reduction of 21.0% from baseline, significantly outperforming placebo which achieved only 2.0% reduction, in adults living with overweight or obesity. The trial successfully met its primary superiority endpoint and showed greater improvements across supportive endpoints, including systolic blood pressure and fasting lipid profile.
- CagriSema, an investigational fixed-dose combination of cagrilintide (an amylin receptor agonist) and semaglutide (a GLP-1 receptor agonist), was well tolerated across both trials, with a safety profile consistent with prior studies. These findings reinforce confidence in CagriSema's potential to offer a potent treatment option for obesity and type 2 diabetes, supporting individualized care through its efficacy, tolerability, and dose flexibility.
CagriSema's Efficacy and Safety in Diabetes and Obesity
Recent clinical and real-world evidence across several interventions highlights meaningful advances in glycemic control, cardiovascular risk reduction, and weight management in type 2 diabetes. The studies below span pharmacological classes — from SGLT2 inhibitors and GLP-1 receptor agonists to dual GIP/GLP-1 agonists — offering comparative insights relevant to both clinical and strategic decision-making.
| Study Name | Intervention(s) | Key Efficacy Outcomes | Key Safety Outcomes |
|---|---|---|---|
| DECLARE-like cohort (Swedish nationwide observational study, 2020) | Dapagliflozin vs. other glucose-lowering drugs | 21% lower risk of HHF or CV mortality (HR 0.79, 95% CI 0.69–0.92); HHF HR 0.79 (95% CI 0.67–0.93); CV mortality HR 0.75 (95% CI 0.57–0.97); no significant association with MACE (HR 0.90, 95% CI 0.79–1.03) | No significant association with myocardial infarction (HR 0.91, 95% CI 0.74–1.11) or stroke (HR 1.06, 95% CI 0.87–1.30) |
| SURPASS-2 (post hoc analysis, 2025) | Tirzepatide (5, 10, 15 mg) vs. semaglutide 1 mg | 57% of tirzepatide 15 mg patients met ≥3 standard targets vs. 34% with semaglutide; 29% met ≥3 intensive targets with tirzepatide 15 mg vs. 8% with semaglutide; HbA1c <53 mmol/mol OR 1.50 (95% CI 1.12–2.00); weight loss >15% OR 3.86 (95% CI 2.69–5.55) | Not reported |
| Semaglutide + basal insulin meta-analysis (2025) | Semaglutide combined with basal insulin vs. placebo or active comparator | HbA1c reduction MD −1.17% (P < 0.00001); body weight reduction MD −5.99 kg (P < 0.00001); FPG reduction MD −1.08% (P < 0.00001) | No increased risk of adverse events (RR 1.46, P = 0.13); no increased hypoglycemia risk; increased gastrointestinal adverse events (nausea, vomiting, diarrhea) |
| Harmony Outcomes / REWIND / Tayside Bioresource — IMI2 SOPHIA study (2024) | GLP-1-based therapies (placebo arms of REWIND, EMPA-REG OUTCOME); real-world cohort | +1 SD increase in BMI variability associated with HR 1.12 (95% CI 1.08–1.17, P < 0.001) for 3P-MACE in Harmony Outcomes; most variable quartile had 87% higher 3P-MACE risk (P < 0.001) vs. least variable | BMI variability's impact on 3P-MACE was independent of HbA1c variability; association not replicated in EMPA-REG OUTCOME |
| GENERATION (2016) | Saxagliptin 5 mg/day vs. glimepiride ≤6 mg/day (added to metformin) in patients ≥65 years | Similar proportions achieved HbA1c <7.0% without confirmed/severe hypoglycaemia (37.9% saxagliptin vs. 38.2% glimepiride; OR 0.99, 95% CI 0.73–1.34; p = 0.9415) | Confirmed/severe hypoglycaemia: 1.1% saxagliptin vs. 15.3% glimepiride (nominal p < 0.0001); similar overall adverse event incidence between groups |
Key Design and Endpoints of REIMAGINE 5 and REDEFINE 9
Several key trials across Type 2 diabetes have evaluated glucose-lowering agents, SGLT2 inhibitors, and fixed-ratio combinations, each with distinct design parameters and endpoints informing cardiovascular, renal, and glycaemic outcomes.
| Trial / Study | Design | Population | Key Endpoints | Notable Results |
|---|---|---|---|---|
| DECLARE-TIMI 58 | Randomised, placebo-controlled; median follow-up 4.2 years | 17,160 patients with T2D with or at risk for atherosclerotic cardiovascular disease | Primary safety: MACE (CV death, MI, ischaemic stroke); Primary efficacy: MACE and CV death or hospitalisation for HF; Secondary: renal composite (≥40% decrease in eGFR to <60 ml/min/1.73 m², new ESRD, or death from renal or CV causes), all-cause death | Dapagliflozin non-inferior to placebo for MACE; lower rate of CV death or hospitalisation for HF (4.9% vs. 5.8%; HR 0.83, 95% CI 0.73–0.95; P=0.005), driven by lower hospitalisation for HF (HR 0.73, 95% CI 0.61–0.88); renal event 4.3% vs. 5.6% (HR 0.76, 95% CI 0.67–0.87) |
| GLP-1 RA meta-analysis (Cochrane, 2025) | Systematic review and meta-analysis of 42 RCTs | 48,148 participants with T2D and CKD (all stages); median age 66 years; median follow-up 26 weeks | Primary: all-cause death, CV death, 3- and 4-point MACE, kidney failure, composite kidney outcome, severe hypoglycaemia | GLP-1 RAs probably reduced all-cause death vs. placebo (RR 0.85, 95% CI 0.74–0.98; moderate certainty); probably decreased 3-point MACE (RR 0.84, 95% CI 0.73–0.98; moderate certainty); probably little or no effect on kidney failure (RR 0.86, 95% CI 0.66–1.13; moderate certainty) |
| Soli-SWITCH | Phase 4, 24-week, single-arm | 162 adults with T2D switching from premixed insulin; HbA1c ≥7.5%–≤10.0% | Primary: change in HbA1c from baseline to Week 24; Secondary: proportion achieving HbA1c <7%, body weight change, safety | LS mean HbA1c reduction of 1.2% (95% CI: −1.4, −1.1); 37.6% achieved HbA1c <7%; LS mean body weight change −1.0 kg (95% CI: −1.6, −0.5); confirmed symptomatic hypoglycaemia in 38.3% |
| STAR.Ro | Open-label, 24-week, prospective cohort | 876 Romanian adults with T2D suboptimally controlled on OADs ± basal insulin initiating iGlarLixi | Primary: change in HbA1c from baseline to Week 24; Secondary: proportion reaching HbA1c targets, change in FPG | Mean HbA1c change −1.3% (95% CI: −1.4% to −1.2%; p<0.0001); mean FPG change −3.1 mmol/L (95% CI: −3.3 to −2.8; p<0.001); mean body weight change −1.6 kg (95% CI: −1.9 to −1.3; p<0.001); symptomatic hypoglycaemia in 1.5% |
| DURABLE trial (Argentina subgroup) | Post-hoc analysis of 24-week RCT initiation phase | 193 insulin-naïve T2D patients (ages 30–79) inadequately controlled on ≥2 OAMs | Primary: HbA1c at 24-week endpoint; Secondary: proportion achieving HbA1c ≤6.5% and ≤7.0%, body weight change, self-monitored BG, hypoglycaemia rates | LM25 showed greater HbA1c reduction vs. glargine (−2.4% vs. −2.0%; P=0.002); higher proportion achieving HbA1c ≤7.0% (P=0.012); greater body weight gain with LM25 (6.35 kg vs. 4.23 kg; P<0.001); no difference in hypoglycaemia rates |
| Taiwan SGLT2i/Pioglitazone cohort | Real-world, propensity-matched nationwide cohort (4 groups, 15,601 patients each) | T2DM patients without prior cardiovascular disease | Primary: 3-point MACE (MI, stroke, CV death); Secondary: incidence of heart failure | Combination pioglitazone/SGLT2i: lower MACE risk (aHR 0.76, 95% CI 0.66–0.88) and HF risk (aHR 0.67, 95% CI 0.55–0.82) vs. reference; SGLT2i alone: significantly decreased HF incidence (aHR 0.7, 95% CI 0.58–0.86) |
CagriSema's Position Against Tirzepatide in Weight Management
Tirzepatide, a dual GIP and GLP-1 receptor agonist, has demonstrated substantial efficacy against placebo and active comparators across multiple randomized controlled trials in Type 2 diabetes (T2D). A network meta-analysis of ten studies found that tirzepatide 10 mg and 15 mg produced significant HbA1c reductions of 19% and 31%, respectively, relative to the 5 mg dose (MD: −0.19 and MD: −0.32), alongside notable weight reductions (MD: −1.96 and MD: −3.31). The 15 mg dose additionally achieved significant reductions in fasting serum glucose (MD: −6.71). In cardiovascular outcomes research, a network meta-analysis of 34 trials found that tirzepatide 15 mg significantly reduced stroke risk, while semaglutide regimens showed the most consistent reductions in MACE and myocardial infarction versus placebo.
Retatrutide, a first-in-class unimolecular triple agonist targeting GLP-1, GIP, and glucagon receptors, represents the most advanced next-generation candidate beyond tirzepatide. Phase 2 data in patients with T2D demonstrated an absolute HbA1c reduction of 2.02%–2.2%, with 82% of participants reaching HbA1c ≤6.5% and 27% achieving normoglycemia (HbA1c <5.7%). Retatrutide also produced an 8.79 mm Hg reduction in systolic blood pressure, an 82%–82.4% relative reduction in hepatic fat, and significant attenuation of the urine albumin-to-creatinine ratio — a cardiometabolic and renal benefit profile that extends well beyond glycemic control alone.
SGLT2 inhibitors, an established standard-of-care class, provide a complementary cardiovascular and renal risk reduction profile. A large real-world cohort study (209,867 matched pairs) found that SGLT2 inhibitors were associated with decreased risks of MACE (hazard ratio 0.76, 95% CI 0.69–0.84), cardiovascular death (HR 0.60, 95% CI 0.54–0.67), heart failure (HR 0.43, 95% CI 0.37–0.51), and all-cause mortality (HR 0.60, 95% CI 0.54–0.67) compared with DPP-4 inhibitors. Network meta-analysis further suggested that combining semaglutide with SGLT2 inhibition produced the strongest MACE reduction observed across agents, and that UACR showed marked reductions with dulaglutide plus dapagliflozin — underscoring the additive potential of combining incretin-based and SGLT2-based therapies in high-risk T2D populations.
CagriSema's Ascent: A New Force in Metabolic Treatment
The recent topline results for Novo Nordisk's CagriSema mark a significant moment in the ongoing evolution of metabolic disease pharmacotherapy. In a landscape increasingly dominated by highly effective incretin-based therapies, CagriSema, a novel GLP-1/amylin co-agonist, has demonstrated compelling efficacy that could reshape treatment paradigms for type 2 diabetes and obesity. The head-to-head comparison against tirzepatide 5 mg, a dual GIP/GLP-1 receptor agonist, is particularly noteworthy. CagriSema's superior weight loss in type 2 diabetes patients, alongside substantial reductions in body weight for individuals with overweight or obesity, positions it as a potent contender in a market where efficacy is paramount.
This success underscores the strategic importance of developing next-generation therapies that build upon the foundation of GLP-1 receptor agonism. The addition of an amylin receptor agonist, cagrilintide, to semaglutide leverages a synergistic mechanism, influencing hunger, gastric motility, and energy metabolism in a way that appears to drive enhanced weight loss. This approach could offer a differentiated profile in a crowded market, potentially appealing to patients and clinicians seeking maximum weight reduction and glycemic control.
However, several considerations warrant attention. While CagriSema outperformed tirzepatide 5 mg, it is important to acknowledge that higher doses of tirzepatide are available and have shown greater efficacy. Future comparisons against these higher doses will be crucial for a complete understanding of CagriSema's competitive standing. Furthermore, while the safety profile was reported as consistent, the known gastrointestinal adverse events associated with GLP-1 receptor agonists remain a factor in patient tolerability and adherence. As with any emerging therapy, long-term data on CagriSema's sustained efficacy, safety, and potential disease-modifying effects beyond weight loss will be essential to solidify its place in chronic metabolic management. These results, nonetheless, signal a strong move by Novo Nordisk to maintain its leadership in a rapidly advancing therapeutic area.
Frequently Asked Questions
References
- [1] Valentine WJ, Hoog M et al.. Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States. Diabetes, obesity & metabolism. 2023 May. 36655340
- [2] Günes-Altan M, Bosch A et al.. Is GFR decline induced by SGLT2 inhibitor of clinical importance?. Cardiovascular diabetology. 2024 May 29. 38811998
- [3] Massey RJ, Chen Y et al.. BMI variability and cardiovascular outcomes within clinical trial and real-world environments in type 2 diabetes: an IMI2 SOPHIA study. Cardiovascular diabetology. 2024 Jul 16. 39014446
- [4] Xie X, Yang S et al.. Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis. Frontiers in pharmacology. 2025. 41050409
- [5] Brock C, Andersen H et al.. Barriers and new opportunities in developing effective therapies for diabetic neuropathy: International expert consensus recommendations. Diabetes research and clinical practice. 2025 Mar. 39855602
- [6] Pillai AA, Godin SL et al.. Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review. Cardiology in review. 2026 May 11. 42108533
- [7] Karrar HR, Nouh MI et al.. Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis. Cureus. 2023 Sep. 37908927
- [8] Chen B, Tao L et al.. Efficacy and safety of combination of semaglutide and basal insulin in patients with of type 2 diabetes mellitus: A systematic review and meta-analysis. Clinical nutrition ESPEN. 2025 Apr. 39892787
- [9] Wiviott SD, Raz I et al.. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine. 2019 Jan 24. 30415602
- [10] Bala C, Cerghizan A et al.. Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro). BMJ open. 2022 May 27. 35623748
- [11] Savarese G, Settergren C et al.. Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. International journal of cardiology. 2020 Aug 15. 32360702
- [12] Niu S, Alkhuzam KA et al.. 5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine. Diabetes, obesity & metabolism. 2024 Feb. 37867175
- [13] Goldney J, Hamza M et al.. Triple Agonism Based Therapies for Obesity. Current cardiovascular risk reports. 2025. 40741227
- [14] Pham TP, Vo TM et al.. Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis. Diabetes, obesity & metabolism. 2026 Jun. 41804851
- [15] Neves JS, Leite AR et al.. Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial. Diabetologia. 2026 May. 41419618
- [16] Schernthaner G, Durán-Garcia S et al.. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, obesity & metabolism. 2015 Jul. 25761977
- [17] Fernández Landó L, Massari F et al.. [Starting an insulin regimen with insulin lispro mix 25 versus glargine insulin for type 2 diabetes]. Medicina. 2012. 22763161
- [18] Jiang Y, Zhu H et al.. Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes?. Diabetes, obesity & metabolism. 2025 Mar. 39592891
- [19] Lo SC, Kornelius E et al.. Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database. Diabetes research and clinical practice. 2023 Jun. 37100230
- [20] Norhammar A, Bodegård J et al.. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study. Diabetes, obesity & metabolism. 2019 May. 30609272
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
